153 related articles for article (PubMed ID: 38317132)
1. Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis.
Wang T; Liu H; Huang H; Weng Y; Wang X
BMC Infect Dis; 2024 Feb; 24(1):161. PubMed ID: 38317132
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Demirlenk YM; Gücer LS; Uçku D; Tanrıöver C; Akyol M; Kalay Z; Barçın E; Akcan RE; Can F; Gönen M; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):761-769. PubMed ID: 35303195
[TBL] [Abstract][Full Text] [Related]
3. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Huang PH; Chen WY; Chou SH; Wang FD; Lin YT
Microbiol Spectr; 2022 Jun; 10(3):e0038122. PubMed ID: 35652641
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: A systematic review and meta-analysis.
Li D; Rao H; Xu Y; Zhang M; Zhang J; Luo J
J Infect Chemother; 2024 May; 30(5):372-378. PubMed ID: 38369125
[TBL] [Abstract][Full Text] [Related]
6. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae.
Balkan II; Alkan M; Aygün G; Kuşkucu M; Ankaralı H; Karagöz A; Şen S; Arsu HY; Biçer M; Kaya SY; Karaali R; Mete B; Saltoğlu N; Tabak F
Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2161-2170. PubMed ID: 33963928
[TBL] [Abstract][Full Text] [Related]
7. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: A systematic review and meta-analysis.
Hou SY; Wu D; Feng XH
J Glob Antimicrob Resist; 2020 Dec; 23():197-202. PubMed ID: 33091620
[TBL] [Abstract][Full Text] [Related]
8. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
9. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
10. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
12. Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape.
Giacobbe DR; Marelli C; Cattardico G; Fanelli C; Signori A; Di Meco G; Di Pilato V; Mikulska M; Mazzitelli M; Cattelan AM; Pallotto C; Francisci D; Calabresi A; Lombardi A; Gori A; Del Bono V; Aldieri C; Losito AR; Raffaelli F; Cortegiani A; Milazzo M; Del Puente F; Pontali E; De Rosa FG; Corcione S; Mularoni A; Russelli G; Giacomini M; Badalucco Ciotta F; Oltolini C; Serino FS; Momesso E; Spinicci M; Graziani L; Torti C; Trecarichi EM; Merli M; D'Amico F; Marchese A; Vena A; Bassetti M
J Antimicrob Chemother; 2023 Oct; 78(10):2505-2514. PubMed ID: 37606528
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.
Demiraslan H; Dinc G; Ahmed SS; Elmali F; Metan G; Alp E; Doganay M
J Chemother; 2014 Oct; 26(5):276-81. PubMed ID: 24070112
[TBL] [Abstract][Full Text] [Related]
14. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.
De Pascale G; Martucci G; Montini L; Panarello G; Cutuli SL; Di Carlo D; Di Gravio V; Di Stefano R; Capitanio G; Vallecoccia MS; Polidori P; Spanu T; Arcadipane A; Antonelli M
Crit Care; 2017 Jul; 21(1):173. PubMed ID: 28679413
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.
Giannella M; Graziano E; Marconi L; Girometti N; Bartoletti M; Tedeschi S; Tumietto F; Cristini F; Ambretti S; Berlingeri A; Lewis RE; Viale P
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1965-1970. PubMed ID: 28567543
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors Affecting Patterns of Antibiotic Resistance and Treatment Efficacy in Extreme Drug Resistance in Intensive Care Unit-Acquired Klebsiella Pneumoniae Infections: A 5-Year Analysis.
Durdu B; Meric Koc M; Hakyemez IN; Akkoyunlu Y; Daskaya H; Sumbul Gultepe B; Aslan T
Med Sci Monit; 2019 Jan; 25():174-183. PubMed ID: 30614487
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
18. Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract.
Zhang R; Dong N; Huang Y; Zhou H; Xie M; Chan EW; Hu Y; Cai J; Chen S
Emerg Microbes Infect; 2018 Jul; 7(1):127. PubMed ID: 29985412
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
[TBL] [Abstract][Full Text] [Related]
20. Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms.
Geladari A; Simitsopoulou M; Antachopoulos C; Roilides E
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
